ALT

Over the past six months, Altimmune's stock price trended up by 2.10%, though it experienced a 1-year change of -16% to -17.93% as of mid-September 2026. Key events impacting the stock include positive topline results from its RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder in July 2026, which led to an 18% surge in shares, and positive 48-week data from the IMPACT Phase 2b trial in MASH announced in December 2025. Regulatory designations from the FDA, such as Fast Track for MASH and AUD, and Breakthrough Therapy Designation for MASH, have accelerated its development. The company announced its Second Quarter 2026 financial results and business update on August 12, 2026, reporting a net loss of $22.8 million for the quarter but growing cash reserves above $518 million. Altimmune has participated in various healthcare conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Stifel Cardiometabolic Forum. Insider activity included an executive gaining 24,000 RSUs in September 2026 and the CEO purchasing 15,000 shares in August 2026. In June 2026, the company announced plans to move its corporate headquarters, which is expected to support talent attraction and long-term cost efficiencies. Despite positive company-specific news, Altimmune's stock has at times been impacted by broader healthcare sector weakness, rising Treasury yields, and concerns over inflation and interest rates, reflecting the inherent volatility of biotech stocks.